A
Acticor Biotech
Safe and effective treatment of stroke
About Acticor Biotech
Acticor Biotech is a clinical-stage biotechnology company focused on developing innovative treatments for acute thrombotic diseases, particularly acute ischemic stroke. Founded in 2013 as a spin-off from INSERM, the company leverages academic research to create therapeutic monoclonal antibodies. Acticor Biotech's primary drug candidate, Glenzocimab, is designed to inhibit glycoprotein VI, a key player in collagen-induced platelet aggregation, which is crucial in the formation of blood clots. The company has successfully completed the first phase of its ACTIMIS study, demonstrating promising results in patients with acute ischemic stroke.
Read full description
Acticor Biotech operates in the biopharmaceutical market, targeting healthcare providers and patients affected by stroke and other thrombotic conditions. The business model revolves around the development, clinical testing, and eventual commercialization of its drug candidates. Revenue is primarily generated through partnerships, licensing agreements, and future sales of approved treatments.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Paris, France
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, observatoire industrial tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2019 | $7.7M | $31M | Newton BioCapital · Anaxago · Karista · GO Capital | — |
| SERIES B✓Equity / VC | Oct 2018 | $17M | $67M | Primer Capital · Mirae Asset Capital · Karista · Newton BioCapital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Acticor Biotech is 680 monthly website visits, up 423.1% over the last three months. Acticor Biotech's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
Anaxago
Karista- PCPrimer Capital
Newton BioCapital
Mirae Asset Capital
GO Capital
Other known investors9 additional known investors
Ouest Valorisation
CNRS Innovation
French National Centre for Scientific Research - CNRS
University of Western Brittany
Agile Capital Markets
Agoranov
Alexandre Heraud
CapHorn
Paris Biotech Santé
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acticor Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acticor Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.